Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech

Bharat Biotech International Limited (BBIL) on Friday announced that its COVID-19 vaccine Covaxin has proven to be safe, well-tolerated and highly immunogenic in paediatric subjects in phase II/III study. A press release from the vaccine maker said the study has been accepted and published in Lancet Infectious diseases, peer reviewed high impact factor journal.

Credits – Source – https://ift.tt/uyj2v8b

The post Covaxin safe, well-tolerated in 2-18 years age-group: Bharat Biotech appeared first on Stay in Gurgaon.

Comments

Popular posts from this blog

Flat sale of flu drugs hints at no unusual rise in infections

10YearsForSimha: Reasons behind film’s success

Hrithik-Saif’s Vikram Vedha hits a roadblock